Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

Principal Investigator
Name
Amanda Black
Institution
NCI, DCEG, EBP
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2008-0036
Initial CDAS Request Approval
Sep 11, 2008
Title
Baseline PSA and 7 Year Risk of Prostate Cancer Diagnosis
Summary
Considerable controversy still remains over the use of PSA screening for the early detection of prostate cancer. Where the American Cancer Society and the American Urological Association recommend annual screening for prostate cancer, using PSA testing and digital rectal examinations, the UK has no such recommendations. The PCPT has demonstrated that there is no 'normal' PSA but rather a continuum of risk of prostate cancer based on the individual's PSA level. This contributes to the uncertainty of the most appropriate level, and how intensively, to investigate low PSA levels. There is a need to balance over-diagnosis of prostate cancer with identification of clinically significant cancers. To allow men to make a fully informed choice when both considering and following a PSA test, they must be aware of the outcomes associated with their options. The US PCPT and PLCO cancer trials and the Northern Ireland PSA study have all attained at least 7 years of follow-up for all study participants since their baseline PSA test. These studies offer the opportunity to compare the risk of prostate cancer diagnosis in a variety of environments (biopsy all, annual screening, non-screening).
Aims

This would be a two-phase project. The first phase would involve investigation of the risk of prostate cancer diagnosis based on baseline PSA after 7 years of follow-up in PLCO. Aim 1.To investigate the 7 year risk of prostate cancer diagnosis and grade of disease based on baseline PSA measurements in men undergoing screening in the PLCO trial. The second phase would seek to retrieve raw data from PCPT collaborators and NI collaborators . Aim 2. To compare the risk of prostate cancer diagnosis and grade of disease following 7 years of follow-up after baseline PSA test in 3 differing environments: biopsy all men (PCPT), screening (PLCO), non-screened population (NI).

Collaborators

Charles L. Bennett, M.D., Ph.D., M.P.P. (Northwestern University)
David Crawford (University of Colorado)
Robert Grubb (Wash U, St Louis, Missouri)
Paul Pinsky (EDRG, NCI)
Lauren Houghton, DCEG